2025中国细胞与基因治疗大会在京开幕 中国细胞与基因治疗联盟宣告成立

Core Insights - The China Cell and Gene Therapy Conference (CSGCT) was held in Beijing, highlighting the city's leadership in the medical device sector and its projected pharmaceutical and health industry scale of 1.06 trillion yuan in 2024, marking an 8.7% year-on-year growth [1] - Beijing's Haidian District is leveraging its educational and medical resources to foster innovation in the cell and gene therapy (CGT) field, aiming to transition from a "follower" to a "leader" in the industry [1][2] Industry Development - Haidian District is enhancing its original innovation capabilities and creating a world-class business environment to promote the full-chain development of the CGT industry, supported by action plans and measures [2] - The establishment of the China Cell and Gene Therapy Alliance aims to facilitate international collaboration and resource sharing in the CGT sector [2][3] Innovation and Collaboration - A global future pharmaceutical and health industry incubation platform is being developed, focusing on core technology areas such as CGT, multi-omics, precision medicine, brain-computer interfaces, and AI healthcare [3] - The conference featured discussions on global CGT opportunities and challenges, with participation from international experts and local industry leaders to strategize on China's global CGT development [3][4] Investment and Financing - The conference included project roadshows for gene therapy, nucleic acid drugs, gene editing, and immunotherapy, providing a platform for innovative companies to connect with international capital [3] - Notable investment institutions like Eli Lilly Asia Fund and Junlian Capital participated in the event to support companies in expanding their financing channels and accelerating internationalization [3]